Full Text Journal Articles by
Author Peter Albers

Advertisement

Find full text journal articles






Late relapsing germ cell tumors with elevated tumor markers.

Yue Che, Achim Lusch, Christian Winter, Robert Große Siemer, Carolin Buddensieck, Peter Albers, Andreas Hiester,

<h4>Purpose</h4>Late relapsing germ cell tumors (LR-GCT) are considered a rare distinct biologic entity as their clinical presentation and response to treatment is different to early recurrences. While serum tumor markers (AFP and ß-HCG) play an important role at the time of first diagnosis to correctly classify prognosis and treatment of ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.

Hendrik Van Poppel, Renée Hogenhout, Peter Albers, Roderick C N van den Bergh, Jelle O Barentsz, Monique J Roobol,

<h4>Context</h4>Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid since the introduction of new technologies such as risk calculators (RCs) and magnetic resonance imaging (MRI). These new technologies result in fewer unnecessary biopsy procedures and fewer cases of both overdiagnosis and underdetection. Therefore, we can now ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.

Andreas Hiester, Anna Fingerhut, Günter Niegisch, Roswitha Siener, Susanne Krege, Hans-Ulrich Schmelz, Klaus-Peter Dieckmann, Axel Heidenreich, Peter Kwasny, Maik Pechoel, Jan Lehmann, Sabine Kliesch, Kai-Uwe Köhrmann, Rolf Fimmers, Volker Loy, Christian Wittekind, Michael Hartmann, Peter Albers,

<h4>Background</h4>One cycle of adjuvant chemotherapy with bleomycin, etoposide and cisplatin (BEP) has shown superiority in recurrence-free survival over retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) I non-seminomatous germ cell tumours (NSGCTs) of the testis in the setting of a phase III trial. We report the recurrences ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 155:64-72]

Cited: 0 times

View full text PDF listing >>



The developmental origin of cancers defines basic principles of cisplatin resistance.

Margaretha A Skowron, Christoph Oing, Felix Bremmer, Philipp Ströbel, Matthew J Murray, Nicholas Coleman, James F Amatruda, Friedemann Honecker, Carsten Bokemeyer, Peter Albers, Daniel Nettersheim,

Cisplatin-based chemotherapy has been used for more than four decades as a standard therapeutic option in several tumor entities. However, being a multifaceted and heterogeneous phenomenon, inherent or acquired resistance to cisplatin remains a major obstacle during the treatment of several solid malignancies and inevitably results in disease progression. Hence, ... Read more >>

Cancer Lett (Cancer letters)
[2021, 519:199-210]

Cited: 0 times

View full text PDF listing >>



Addressing Equality of Representation in Urology Societies.

Christopher R Chapple, Peter Albers, John Denstedt,

Eur Urol (European urology)
[2021, 80(4):454-455]

Cited: 0 times

View full text PDF listing >>



The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas.

Margaretha A Skowron, Teresa K Becker, Lukas Kurz, Sina Jostes, Felix Bremmer, Florian Fronhoffs, Kai Funke, Gamal A Wakileh, Melanie R Müller, Aaron Burmeister, Thomas Lenz, Anja Stefanski, Kai Stühler, Patrick Petzsch, Karl Köhrer, Peter Altevogt, Peter Albers, Glen Kristiansen, Hubert Schorle, Daniel Nettersheim,

Testicular germ cell tumors (GCTs) are stratified into seminomas and nonseminomas. Seminomas share many histological and molecular features with primordial germ cells, whereas the nonseminoma stem cell population-embryonal carcinoma (EC)-is pluripotent and thus able to differentiate into cells of all three germ layers (teratomas). Furthermore, ECs are capable of differentiating into ... Read more >>

Mol Oncol (Molecular oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.

Carlo A Bravi, Matteo Droghetti, Nicola Fossati, Giorgio Gandaglia, Nazareno Suardi, Elio Mazzone, Vito Cucchiara, Simone Scuderi, Francesco Barletta, Riccardo Schiavina, Daniar Osmonov, Klaus-Peter Juenemann, Luca Boeri, R Jeffrey Karnes, Alexander Kretschmer, Alexander Buchner, Christian Stief, Andreas Hiester, Alessandro Nini, Peter Albers, Gaëtan Devos, Steven Joniau, Hendrik Van Poppel, Bernhard Grubmüller, Shahrokh F Shariat, Axel Heidenreich, David Pfister, Derya Tilki, Markus Graefen, Inderbir S Gill, Alexandre Mottrie, Pierre I Karakiewicz, Francesco Montorsi, Alberto Briganti,

<h4>Background</h4>The optimal definition and prognostic significance of persistently elevated prostate-specific antigen (PSA) after salvage lymph node dissection (sLND) for node-only recurrent prostate cancer (PCa) remain unknown.<h4>Objective</h4>To assess the definition and clinical implications of persistently elevated PSA after sLND for node-only recurrent PCa after radical prostatectomy.<h4>Design, setting, and participants</h4>The study included ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.

Thomas Powles, Zoe June Assaf, Nicole Davarpanah, Romain Banchereau, Bernadett E Szabados, Kobe C Yuen, Petros Grivas, Maha Hussain, Stephane Oudard, Jürgen E Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard G Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan,

Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse<sup>1</sup>. We evaluated outcomes in 581 patients who had undergone surgery and were ... Read more >>

Nature (Nature)
[2021, 595(7867):432-437]

Cited: 2 times

View full text PDF listing >>



[Prostate cancer screening 2021 : Individualization, informed decision-making and additional diagnostic options are good for the disease and those affected].

Maurice Stephan Michel, Peter Albers,

Urologe A (Der Urologe. Ausg. A)
[2021, 60(5):565-566]

Cited: 0 times

View full text PDF listing >>



Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy.

Hendrik Van Poppel, Renée Hogenhout, Peter Albers, Roderick C N van den Bergh, Jelle O Barentsz, Monique J Roobol,

Eur Urol (European urology)
[2021, 80(1):e28-e29]

Cited: 0 times

View full text PDF listing >>



Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?

Phillip Woodruff, Christopher J D Wallis, Peter Albers, Zachary Klaassen,

Virtual conferences rapidly became the norm during the COVID-19 pandemic. Although necessary, there are shortfalls to strictly virtual meetings, including less enthusiasm for submitting abstracts. An approach that combines in-person attendance and virtual platforms may be an optimal compromise both during the ongoing pandemic and moving forward. ... Read more >>

Eur Urol (European urology)
[2021, 80(2):127-128]

Cited: 1 time

View full text PDF listing >>



Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Thomas Wiegel, Peter Albers, Detlef Bartkowiak, Roswitha Bussar-Maatz, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Heinz Schmidberger, Klaus Grozinger, Peter Renner, Fried Schneider, Martin Burmester, Michael Stöckle,

J Cancer Res Clin Oncol (Journal of cancer research and clinical oncology)
[2021, 147(4):1273-1274]

Cited: 0 times

View full text PDF listing >>



Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Joaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, Peter Albers, Stephane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H O'Donnell, Jonathan E Rosenberg, Daniel M Geynisman, Daniel P Petrylak, Jean Hoffman-Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S van der Heijden, Cora N Sternberg, Nicole N Davarpanah, Thomas Powles, ,

<h4>Background</h4>Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma.<h4>Method</h4>In the IMvigor010 study, a ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(4):525-537]

Cited: 8 times

View full text PDF listing >>



Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention.

Clarissa Gillmann, Gabor Pajor, Pierluigi Ramadori, Peter Albers, Ute Mons, Karen Steindorf, Susan Kentner, Michael Baumann,

The 2nd International DKFZ Conference on Cancer Prevention (CCP2020) organized by the German Cancer Research Center (DKFZ) was held as a virtual event on 17-18 September 2020. The event gathered experts on cancer prevention from around the world with the aim of generating a stimulating interchange of opinions between clinicians ... Read more >>

Int J Cancer (International journal of cancer)
[2021, 148(12):3086-3096]

Cited: 0 times

View full text PDF listing >>



Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.

Christian Daniel Fankhauser, Jan Oldenburg, Peter Albers, Ferran Algaba, Carsten Bokemeyer, Joost L Boormans, Stefanie Fischer, Karim Fizazi, Hendrik Gremmels, Javier Mayor de Castro, Florian Janisch, Tim Muilwijk, Ricardo Leão, David Nicol, Nicola Nicolai, Torgrim Tandstad, M Pilar Laguna,

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient. ... Read more >>

Eur Urol (European urology)
[2021, 80(1):4-6]

Cited: 0 times

View full text PDF listing >>



Testicular germ cell tumors.

Peter Albers,

Asian J Urol (Asian journal of urology)
[2021, 8(2):143]

Cited: 0 times

View full text PDF listing >>



Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).

Jens-Uwe Stolzenburg, Sigrun Holze, Petra Neuhaus, Iason Kyriazis, Hoang Minh Do, Anja Dietel, Michael C Truss, Corinn I Grzella, Dogu Teber, Markus Hohenfellner, Robert Rabenalt, Peter Albers, Meinhard Mende,

<h4>Background</h4>The LAP-01 trial was designed to address the lack of high-quality literature comparing robotic-assisted (RARP) and laparoscopic (LRP) radical prostatectomy.<h4>Objective</h4>To compare the functional and oncological outcomes between RARP and LRP at 3 mo of follow-up.<h4>Design, setting, and participants</h4>In this multicentre, randomised, patient-blinded controlled trial, patients referred for radical prostatectomy to ... Read more >>

Eur Urol (European urology)
[2021, 79(6):750-759]

Cited: 2 times

View full text PDF listing >>



The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours.

Wasco Wruck, Felix Bremmer, Mara Kotthoff, Alexander Fichtner, Margaretha A Skowron, Stefan Schönberger, Gabriele Calaminus, Christian Vokuhl, David Pfister, Axel Heidenreich, Peter Albers, James Adjaye, Daniel Nettersheim,

Yolk-sac tumours (YSTs), a germ cell tumour subtype, occur in newborns and infants as well as in young adults of age 14-44 years. In clinics, adult patients with YSTs face a poor prognosis, as these tumours are often therapy-resistant and count for many germ cell tumour related deaths. So far, the ... Read more >>

J Cell Mol Med (Journal of cellular and molecular medicine)
[2021, 25(3):1394-1405]

Cited: 1 time

View full text PDF listing >>



[PSMA radioligand therapy could pose infrastructural challenges for nuclear medicine: results of a basic calculation for the capacity planning of nuclear medicine beds in the German hospital sector].

Claus Zippel, Frederik L Giesel, Clemens Kratochwil, Matthias Eiber, Kambiz Rahbar, Peter Albers, Tobias Maurer, Bernd J Krause, Sabine Bohnet-Joschko,

<h4>Background</h4> With the increasing use of the Lu-177-PSMA-RLT for the treatment of advanced castrate resistant prostate cancer (mCRPC), an estimation of the necessary therapy beds in nuclear medicine departments is of great importance in the view of the high number of cases of advanced prostate cancer, and as a basis to ... Read more >>

Nuklearmedizin (Nuklearmedizin. Nuclear medicine)
[2021, 60(3):216-223]

Cited: 1 time

View full text PDF listing >>



Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.

Sabine Kliesch, Stefanie Schmidt, Doris Wilborn, Clemens Aigner, Walter Albrecht, Jens Bedke, Matthias Beintker, Dirk Beyersdorff, Carsten Bokemeyer, Jonas Busch, Johannes Classen, Maike de Wit, Klaus-Peter Dieckmann, Thorsten Diemer, Anette Dieing, Matthias Gockel, Bernt Göckel-Beining, Oliver W Hakenberg, Axel Heidenreich, Julia Heinzelbecker, Kathleen Herkommer, Thomas Hermanns, Sascha Kaufmann, Marko Kornmann, Jörg Kotzerke, Susanne Krege, Glen Kristiansen, Anja Lorch, Arndt-Christian Müller, Karin Oechsle, Timur Ohloff, Christoph Oing, Ulrich Otto, David Pfister, Renate Pichler, Heinrich Recken, Oliver Rick, Yvonne Rudolph, Christian Ruf, Joachim Schirren, Hans Schmelz, Heinz Schmidberger, Mark Schrader, Stefan Schweyer, Stefanie Seeling, Rainer Souchon, Christian Winter, Christian Wittekind, Friedemann Zengerling, D H Zermann, Roger Zillmann, Peter Albers,

<h4>Objectives</h4>We developed the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up of germ cell tumours (GCT) of the testes in adult patients. We present the guideline content in 2 separate publications. The present second part summarizes therecommendations for the treatment of advanced disease stages and for ... Read more >>

Urol Int (Urologia internationalis)
[2021, 105(3-4):181-191]

Cited: 2 times

View full text PDF listing >>



Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.

Hendrik Van Poppel, Renée Hogenhout, Peter Albers, Roderick C N van den Bergh, Jelle O Barentsz, Monique J Roobol,

The burden of prostate cancer is increasing. Therefore, we need to implement a contemporary, organized, risk-stratified program for early detection to reduce both the harm from the disease and potential overdiagnosis and overtreatment, while avoiding underdiagnosis to considerably improve the harm-to-benefit ratio. ... Read more >>

Eur Urol (European urology)
[2021, 79(3):327-329]

Cited: 0 times

View full text PDF listing >>



Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.

Sabine Kliesch, Stefanie Schmidt, Doris Wilborn, Clemens Aigner, Walter Albrecht, Jens Bedke, Matthias Beintker, Dirk Beyersdorff, Carsten Bokemeyer, Jonas Busch, Johannes Classen, Maike de Wit, Klaus-Peter Dieckmann, Thorsten Diemer, Anette Dieing, Matthias Gockel, Bernt Göckel-Beining, Oliver W Hakenberg, Axel Heidenreich, Julia Heinzelbecker, Kathleen Herkommer, Thomas Hermanns, Sascha Kaufmann, Marko Kornmann, Jörg Kotzerke, Susanne Krege, Glen Kristiansen, Anja Lorch, Arndt-Christian Müller, Karin Oechsle, Timur Ohloff, Christoph Oing, Ulrich Otto, David Pfister, Renate Pichler, Heinrich Recken, Oliver Rick, Yvonne Rudolph, Christian Ruf, Joachim Schirren, Hans Schmelz, Heinz Schmidberger, Mark Schrader, Stefan Schweyer, Stefanie Seeling, Rainer Souchon, Christian Winter, Christian Wittekind, Friedemann Zengerling, Dirk-Henrik Zermann, Roger Zillmann, Peter Albers,

<h4>Introduction</h4>This is the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up on germ cell tumours (GCTs) of the testis in adult patients. We present the guideline content in two publications. Part I covers the topic's background, methods, epidemiology, classification systems, diagnostics, prognosis, and treatment recommendations for ... Read more >>

Urol Int (Urologia internationalis)
[2021, 105(3-4):169-180]

Cited: 3 times

View full text PDF listing >>



Clinical dilemmas in local and regional testis cancer.

Gregory J Nason, Ricardo A Rendon, Lori Wood, Robert A Huddart, Peter Albers, Lawrence H Einhorn, Craig R Nichols, Christian Kollmannsberger, Lynn Anson-Cartwright, Padraig Warde, Michael A S Jewett, Peter Chung, Philippe L Bedard, Aaron R Hansen, Robert J Hamilton,

At the Canadian Testis Cancer Workshop, the multidisciplinary management of testis cancer care was discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician's assistants, residents, fellows, nurses, patients, and patient advocacy group members.This review summarizes the discussion regarding clinical dilemmas in local and regional testis cancer. ... Read more >>

Can Urol Assoc J (Canadian Urological Association journal = Journal de l'Association des urologues du Canada)
[2021, 15(1):E58-E64]

Cited: 0 times

View full text PDF listing >>



Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Thomas Wiegel, Peter Albers, Detlef Bartkowiak, Roswitha Bussar-Maatz, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Heinz Schmidberger, Klaus Grozinger, Peter Renner, Fried Schneider, Martin Burmester, Michael Stöckle,

J Cancer Res Clin Oncol (Journal of cancer research and clinical oncology)
[2021, 147(1):243-244]

Cited: 0 times

View full text PDF listing >>



Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

Daniël F Osses, Christian Arsov, Lars Schimmöller, Ivo G Schoots, Geert J L H van Leenders, Irene Esposito, Sebastiaan Remmers, Peter Albers, Monique J Roobol,

We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging-Reporting and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013-2019) from two referral ... Read more >>

J Pers Med (Journal of personalized medicine)
[2020, 10(4):]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0178 s